Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial
The Lancet NeurologyPublished 20 May 2006
Jeremy Chataway, Bernadette Porter, Afsane Riazi, Dominic Heaney, Hilary Watt, Jeremy Hobart
Citations49
SJR quartileQ1
SJR score11.73
SNIP13.75
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Treatment of relapses in multiple sclerosis with intravenous steroids can be effectively and safely administered at home, from both patient and economic perspectives, and has implications for complex service delivery care models for long-term diseases.
Abstract
Treatment of relapses in multiple sclerosis with intravenous steroids can be effectively and safely administered at home, from both patient and economic perspectives. Moreover, the trial indicates the importance of explicit and valid outcome measures of all aspects of service delivery when making decisions about health policy. This finding has implications for complex service delivery care models for long-term diseases.
Keywords
Medicine
NeurologyRating neurologic impairment in multiple sclerosis
14,697 Citations1983John F. Kurtzke
A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 … 9) now divided into two (1.0, 1.5, 2.0 … 9).
Cost-Effectiveness in Health and Medicine
7,119 Citations1996
Annals of NeurologyRecommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
6,953 Citations2001W. I. McDonald, Alistair Compston +14 more
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
BrainTHE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY
1,452 Citations1989Brian G. Weinshenker, B. Bass +5 more
The outcome of multiple sclerosis, assessed according to the Kurtzke Disability Status Scale, was reviewed in 1,099 consecutive patients followed in London, Canada, between 1972 and 1984 and the rate at which disability develops after the onset of a progressive phase of MS is presented.
BrainThe Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure
1,091 Citations2001JC Hobart
Results indicate the MSIS-29 is a clinically useful and scientifically sound patient-based outcome measure of the impact of multiple sclerosis suitable for clinical trials and epidemiological studies.
NeurologyMeasuring the impact of MS on walking ability
783 Citations2003Jeremy Hobart, Afsane Riazi +3 more
The 12-Item MS Walking Scale satisfies standard criteria as a reliable and valid patient-based measure of the impact of MS on walking and was more responsive than other walking-based scales.
BMJ Quality & SafetyPatients' experiences and satisfaction with health care: results of a questionnaire study of specific aspects of care
675 Citations2002C Jenkinson
The evidence suggests that patient satisfaction scores present a limited and optimistic picture and detailed questions about specific aspects of patients’ experiences are likely to be more useful for monitoring the performance of various hospital departments and wards and could point to ways in which delivery of health care could be improved.
The British Journal of PsychiatryClient Socio-Demographic and Service Receipt Inventory – European Version: development of an instrument for international research
492 Citations2000Daniel Chisholm, Martín Knapp +5 more
The CSSRI – EU provides a standardised yet adaptable method for collating service receipt and associated data alongside assessment of patient outcomes and was administered to 404 people with schizophrenia across five countries.
BMJThe national service framework for long term conditions
459 Citations2005Niruj Agrawal, Alex J. Mitchell
This document may go some way towards raising awareness of some of the greatest unmet needs in the NHS for people with long term neurological conditions with a wide range of complex physical, social, and psychological complications.
NeurologyEffect of relapses on development of residual deficit in multiple sclerosis
421 Citations2003Fred Lublin, Monika Baier +1 more
MS exacerbations produce a measurable and sustained effect on disability and the subgroup of patients with measurable change in EDSS during the exacerbation had more extensive residual impairment on the follow-up visits.
BMJCosts and cost-minimisation analysis.
227 Citations1993Ray Robinson
In this second article in the series Ray Robinson defines the types of costs, their measurement, and how they should be valued in monetary terms.
Cochrane Database of Systematic ReviewsCorticosteroids or ACTH for acute exacerbations in multiple sclerosis
203 Citations2000Antonietta Citterio, L. La Mantia +5 more
Evidence favouring the corticosteroid MP for acute exacerbation in MS patients is found and studies assessing long term risk/benefit and adverse effects of Corticosteroids in MS Patients are urgently needed.
British Journal of Community NursingImproving chronic disease management
188 Citations2005Alison While
By 2008 all primary care trusts will be expected to have implemented case management approaches alongside existing initiatives such as the expert patient programme, which will contribute to a reduction in costly unplanned admissions.
BMJCompliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial
158 Citations2001Josep M. Borràs, A Sanchez-Hernandez +6 more
Home chemotherapy seems an acceptable and safe alternative to hospital treatment for patients with colorectal cancer that may improve compliance and satisfaction with treatment.
Journal of Neurology Neurosurgery & PsychiatryMethylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.
149 Citations1993S M Alam, Themis R. Kyriakides +2 more
Oral treatment with methylprednisolone was as effective as intravenous treatment in acute relapse of MS and no significant difference in response when disability or functional scores were compared in the two groups.
European Journal of NeurologyEFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses
142 Citations2005Finn Sellebjerg, David Barnes +7 more
The objective of the task force was to review the literature on treatment of MS relapses to provide evidence‐based treatment recommendations and there is a need for further randomized, controlled trials in order to establish the optimal treatment regimen for relapses of MS.
Multiple Sclerosis JournalA meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations
128 Citations2000Deborah Miller, Bianca Weinstock‐Guttman +9 more
Meta-analyses of published studies assessing MP at different doses and in comparison to other steroid products or no treatment recommend studies to determine optimum benefit related to dosage, timing for starting therapy and the most appropriate GCS type.
Unit Costs of Health and Social Care 2004
52 Citations2004Julie Selwyn, WA Sturgess +2 more
This volume includes a considerable expansion of information about the costs of child social care services, based largely on the results of a series of studies commissioned under the Department of Health's Costs and Effectiveness of Services for Children in Need research initiative.
Journal of Neurology Neurosurgery & PsychiatryUse of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom
47 Citations1998Helen Tremlett, D K Luscombe +1 more
Variability of prescribing recommendations probably reflects a lack of clear evidence in the face of a wide range of clinical situations, variable access, and timing of access to neurologists in the acute phase of relapse and pressure on neurologists to treat in an otherwise “hopeless” situation.